International Myeloma Working Group Consensus Statement for the Management, Treatment, and Supportive Care of Patients With Myeloma Not Eligible for Standard Autologous Stem-Cell TransplantationAntonio Palumbo, Robert Z. Orlowski, Brian G.M. Durie et al.|Journal of Clinical Oncology|2014Cited by 384
Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patientsFrancesca Gay, Antonio Palumbo, Alessandra Larocca et al.|Blood|2011Cited by 268
Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance With Bortezomib-Thalidomide Compared With Bortezomib-Melphalan-Prednisone for Initial Treatment of Multiple Myeloma: Updated Follow-Up and Improved SurvivalAntonio Palumbo, Michèle Cavo, Sara Bringhen et al.|Journal of Clinical Oncology|2014Cited by 210
A phase 2 study of three low-dose intensity subcutaneous bortezomib regimens in elderly frail patients with untreated multiple myelomaAlessandra Larocca, Antonio Palumbo, Sara Bringhen et al.|Leukemia|2016Cited by 46
Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: A retrospective case‐matched studyFortunato Morabito, Massimo Offidani, Sara Galimberti et al.|American Journal of Hematology|2013Cited by 26